

What is claimed is:

1. Use of a pharmaceutical composition comprising a platelet aggregation inhibiting amount of a modified amino acid, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of platelet aggregation.
2. Use according to claim 1 wherein the pharmaceutical composition comprises a pharmacologically active agent and a modified amino acid, or pharmaceutically acceptable salt thereof, wherein the modified amino acid or salt thereof is present in an amount effective to inhibit platelet aggregation for the manufacture of a medicament for the inhibition of platelet aggregation.
3. Use according to claims 1 or 2 wherein the modified amino acid is N-(-5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), or a pharmaceutically acceptable salt thereof.
4. Use according to claim 2 wherein the pharmacologically active agent comprises heparin, insulin, parathyroid hormone or calcitonin and a modified amino acid, or pharmaceutically acceptable salt thereof, wherein the modified amino acid or salt thereof is present in an amount effective to inhibit platelet aggregation for the manufacture of a medicament for the inhibition of platelet aggregation in a mammal receiving heparin, insulin, parathyroid hormone or calcitonin treatment.
5. Use according to claim 4 wherein the mammal is human and the calcitonin is salmon calcitonin.
6. Use according to anyone of claims 1 to 5 wherein the modified amino acid is present in an amount of about 25 mg to about 400 mg .
7. Use according to claim 6 wherein the modified amino acid is present in an amount of about 100 mg to about 200 mg.
8. Use according to anyone of claims 2 to 7, wherein the pharmacologically active agent is present in an amount of 0.05% to 70% by weight relative to the total weight of the pharmaceutical composition.

9. Use according to anyone of claims 2 to 8 wherein the pharmaceutical composition comprises calcitonin and 5-CNAC or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a platelet aggregation inhibiting amount of a modified amino acid, or a pharmaceutically acceptable salt thereof for the inhibition of platelet aggregation.
11. Composition according to claim 10 comprising a pharmacologically active agent and a modified amino acid, or pharmaceutically acceptable salt thereof, wherein the modified amino acid or salt thereof is present in an amount effective to inhibit platelet aggregation for the inhibition of platelet aggregation.
12. A method of inhibiting platelet aggregation in a mammal comprising administering a pharmaceutical composition comprising a platelet aggregation inhibiting amount of a modified amino acid, or a pharmaceutically acceptable salt thereof, to said mammal.
13. Method according to claim 12 comprising administering a pharmaceutical composition comprising a pharmacologically active agent and a modified amino acid, or pharmaceutically acceptable salt thereof, wherein the modified amino acid or salt thereof is present in an amount effective to inhibit platelet aggregation.